Cerus starts phase 1 blood transfusion study

By Elaine Rigoli

Tampa, Fla., Sept. 12 - Cerus Corp. said it started a phase 1 clinical trial of the Intercept red blood cell system, a proprietary system designed to improve blood safety by inactivating blood-borne pathogens in donated red blood cells for transfusion.

The randomized, single-blind, controlled, multi-center study will enroll about 28 patients and compare the recovery and lifespan of autologous red blood cells prepared using a modified S-303 process with conventional, untreated red blood cells.

The primary endpoint is the 24-hour red blood cell recovery post-transfusion. The study is expected to be fully enrolled before year-end and to take about five months to complete.

Cerus is a biopharmaceutical company located in Concord, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.